Stereoselectivity in the organoiron-mediated synthesis of (±)-mesembrine

Tetrahedron Letters

Volumn 49, Issue 4, 2008, Pages 650-653

  Roe, Caroline ^a   Sandoe, Elizabeth J ^a   Stephenson, G Richard ^a   Anson, Christopher E ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF KARLSRUHE   (Germany)

Author keywords

Asymmetric synthesis; Mesembrine; Organometallic electrophiles; Tricarbonyliron

Indexed keywords

ALKALOID DERIVATIVE; INDOLE DERIVATIVE; IRON COMPLEX; MESEMBRINE; ORGANOMETALLIC COMPOUND; POLYCYCLIC AROMATIC HYDROCARBON; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL BOND; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CHIRALITY; STEREOCHEMISTRY; SYNTHESIS;

SCELETIUM;

EID: 37549030187     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2007.11.137     Document Type: Article

References (83)

1. Isolation from Sceletium tortuosum:. Bodendorf K., and Krieger W. Archiv. Pharm. 290 (1957) 441-448
2. structure:. Popelak A., Haack E., Lettenbauer G., and Spingler H. Naturwissenschaften 47 (1960) 156
3. Coggon P., Farrier D.S., Jeffs P.W., McPhail A.T., and Gross P.M. J. Chem. Soc. B (1970) 1267-1271
4. Gericke, N. P.; Van Wyk, B. E. World Patent 9,746,234, 1997
5. Gericke N.P., and Van Wyk B.E. Chem. Abstr. 128 (1998) 80030
6. Owen D.A., Malkov A.V., Palotai I.M., Roe C., Sandoe E.J., and Stephenson G.R. Chem. Eur. J. 13 (2007) 4293-4311
7. Malkov A.V., Auffrant A., Renard C., Rose E., Rose-Munch F., Owen D.A., Sandoe E.J., and Stephenson G.R. Inorg. Chim. Acta 296 (1999) 139-149
8. Jin Z. Nat. Prod. Rep. 24 (2007) 886-905
9. Jin Z. Nat. Prod. Rep. 22 (2005) 111-126
10. Prabhakar S., and Tavares M.R. Alkaloids: Chem. Biol. Perspect. 15 (2001) 433-572
11. Hoshino O. In: Cordell G.A. (Ed). The Alkaloids Vol. 51 (1998), Academic Press, New York 324-424
12. the Amaryllidaceae alkaloids are still a rich source of new potentially biologically active target structures with substantial synthetic challenges:. Unver N. Phytochem. Rev. 6 (2007) 125-135
13. Mason L.H., Puschett E.R., and Wildman W.C. J. Am. Chem. Soc. 77 (1955) 1253-1256
14. Wildman W.C. J. Am. Chem. Soc. 80 (1958) 2567-2575
15. Examples of the biological activity of crinine:. Elgorashi E.E., Stafford G.I., Jager A.K., and van Staden J. Plant. Med. 72 (2006) 470-473 (inhibition of [3H]citalopram binding to the rat brain serotonin transporter)
16. Orhan I., and Sener B. Acta Horticult. (2005) 678 (anticholinesterase activity in Alzheimer's disease patients)
17. Pacheco P., Silva M., Steglich W., and Watson W.H. Rev. Latinoamer. Quim. 9 (1978) 28-32
18. recent example (isolation from Pancratium tortuosum herb):. J. Pharm. Sci. 21 (2007) 61-68
19. structure:. Zabel V., Watson W.H., Pacheco P., and Silva M. Cryst. Struct. Commun. 8 (1979) 371-376
20. Examples of the biological activity of maritidine:. Cea G., Alarcon M., and Weigart G. Med. Sci. 14 (1986) 90 (clastogenic effect/mutagenic)
21. see also Ref. 7a.
22. For examples, see:. Nemoto H. Chem. Pharm. Bull. 55 (2007) 961-974
23. Paul T., Malachowski W.P., and Lee J. Org. Lett. 8 (2006) 4007-4010
24. Taber D.F., and He Y. J. Org. Chem. 70 (2005) 7711-7714 (mesembrine)
25. Bru C., and Guillou C. Tetrahedron 62 (2006) 9043-9048
26. Pearson W.H., and Lovering F.E. J. Org. Chem. 53 (1998) 3607-3617
27. Martin S.F., and Campbell C.L. J. Org. Chem. 53 (1998) 3184-3190 (crinine)
28. Bru C., Thal C., and Guillou C. Org. Lett. 5 (2003) 1845-1846 (maritidine)
29. For our organoiron intermediate for crinine, see Ref. 3.
30. For examples of biological activities of other Amaryllidaceae alkaloids, see: lycoramine:. Han S.Y., Sweeney J.E., Bachman E.S., Schweiger E.J., Forloni G., Coyle J.T., Davis B.M., and Joullie M.M. Eur. J. Med. Chem. 27 (1992) 673-687 (against Alzheimer's disease)
31. Lopez S., Bastida J., Viladomat F., and Codina C. Life Sci. 71 (2002) 2521-2529 (inhibition of acetylcholine esterase)
32. lycorine:. Nino J., Hincapie G.M., Correa Y.M., and Mosquera O.M. Zeit. Naturforsch. C: J. Biosci. 62 (2007) 223-226 (topoisomerase inhibition)
33. galanthamine:. Weinstock M. CNS Drugs 11 (1999) 307-323 (treatment of Alzheimer's disease)
34. Han S.Y., Sweeney J.E., Bachman E.S., Schweiger E.J., Forloni G., Coyle J.T., Davis B.M., and Joullie M.M. Eur. J. Med. Chem. 27 (1992) 673-687 (reversible cholinesterase inhibitor)
35. Sneader W.E. Drug Prototypes and Their Exploitation (1996), Wiley, Chichester
36. 3 analogue of 3, see:. Guillou C., Millot N., Reboul V., and Thal C. Tetrahedron Lett. 37 (1996) 4515-4518
37. 7: (b) For a survey of organoiron complexes, see:. Stephenson G.R. Organometallic Complexes of Iron. In: Lautens M. (Ed). Science of Synthesis. Houben-Weyl Methods of Molecular Transformations Vol. 1 (2001), Georg Theime Verlag, Stuttgart 745-886
38. for earlier reviews of the applications of the cyclohexadienyliron series, see:. Pearson A.J. Acc. Chem. Res. 13 (1980) 463-469
39. Pearson A.J. Synlett (1990) 10-19
40. Knölker H.-J. Synlett (1992) 371-387
41. Donaldson W.A. Aldrichim. Acta 30 (1997) 17-24
42. Knölker H.-J., Braier A., Brocher D.J., Cammerer S., Fröhner W., Gonser P., Hermann H., Herzberg D., Reddy K.R., and Rohde G. Pure Appl. Chem. 73 (2001) 1075-1086
43. Sandoe E.J., Stephenson G.R., and Swanson S. Tetrahedron Lett. 37 (1996) 6283-6286
44. We have developed one pot procedures to add the malononitrile nucleophile and then perform desilylation by addition of TBAF into the reactions mixture (conversion of 2b into 7) and for the reductive amination of the nitrile (conversion of 7 into 8), see Scheme 2.
45. Birch A.J., Cross P.E., Lewis J., White D.A., and Wild S.B. J. Chem. Soc. A (1968) 332-340
46. see also Ref. 17.
47. Stephenson G.R., Finch H., Owen D.A., and Swanson S. Tetrahedron 49 (1993) 5649-5662
48. For a discussion of chirality in such complexes, see:. Stephenson G.R. In: Knochel P. (Ed). Handbook of Functionalised Organometallics (2005), Wiley-VCH, Weinheim 569-626
49. Magdziak D., Pettus L.H., and Pettus T.R.R. Org. Lett. 3 (2001) 557-559
50. Older, J. E. J. PhD Thesis, University of East Anglia, 2001.
51. Older, J. E. J. Stephenson, G. R. unpublished results; ees up to about 40% have been achieved with first generation chiral trityl analogues.
52. Chen C.T., Chao S.D., and Yen K.C. J. Am. Chem. Soc. 119 (1997) 11341-11342
53. Chen. C.T., Chao S.D., and Yen K.C. Synlett (1998) 924-926
54. Chen C.T., and Chao S.D. J. Org. Chem. 84 (1999) 1090-1091
55. The examples reported in this Letter were performed with racemic complexes.
56. Malkov A.V., and Stephenson G.R. J. Organomet. Chem. 489 (1995) C44-C47
57. see also Ref. 4.
58. For the preparation of 3,4-dimethoxyphenyllithium from 3,4-dimethoxybromobenzene in THF at -78 °C, see:. Meyers A.I., and Avila W.B. J. Org. Chem. 46 (1981) 3881-3886
59. a procedure using 3,4-dimethoxyiodobenzene has also been reported:. Capparelli M.P., DeSchepper R.E., and Swenton J.S. J. Org. Chem. 52 (1987) 4953-4957
60. After 5 min to form the aryllithium reagent, the reaction mixture was cooled to -78 °C before addition of the trimethylsilyl chloride.
61. 5-cyclohexadienyl)iron complexes, see:. Birch A.J., Bogsányi D., and Kelly L.F. J. Organomet. Chem. 214 (1981) C39-C42
62. Hudson R.D.A., Osborne S.A., and Stephenson G.R. Tetrahedron 53 (1997) 4095-4104
63. Tranchier J.P., Chavignon R., Prim D., Aufrant A., Giner Planas J., Rose-Munch F., Rose E., and Stephenson G.R. Tetrahedron Lett. 42 (2001) 3311-3313
64. Stephenson G.R., Owen D.A., Finch H., and Swanson S. Aust. J. Chem. 45 (1992) 121-134
65. Howell J.A.S., Bell A.G., O'Leary P.J., Stephenson G.R., Hastings M., Howard P.W., Owen D.A., Whitehead A.J., McArdle P., and Cunningham D. Organometallics 15 (1996) 4247-4257
66. see also Ref. 3.
67. Shvo Y., and Hazum E. Chem. Commun. (1974) 336-337
68. for examples in organoiron-mediated synthesis, see:. Pearson A.J., Ham P., Ong C.W., Perrior T.R., and Rees D.C. J. Chem. Soc., Perkin Trans. 1 (1982) 1527-1534
69. Birch A.J., Kelly L.F., and Weerasuria D.V. J. Org. Chem. 53 (1988) 278-281
70. Bandara B.M.R., Birch A.J., and Kelly L.F. J. Org. Chem. 49 (1989) 4663-4763
71. Pearson A.J., and O'Brien M.K. J. Org. Chem. 54 (1989) 4663-4673
72. Knölker H.-J., Baum E., and Reddy K.R. Tetrahedron Lett. 41 (2000) 1171-1174
73. Knölker H.-J., and Hopfmann T. Tetrahedron 58 (2002) 8937-8945
74. 1H NMR spectrum of mesembrenone:. Jeffs P.W., Ahmann G., Campbell H.F., Farrier D.S., Ganguli G., and Hawks R.L. J. Org. Chem. 35 (1970) 3512-3518
75. 13C NMR data, see:. Jeffs P.W., Capps T., Johnson D.B., Karle J.M., Martin N.H., and Rauckman B. J. Org. Chem. 39 (1974) 2703-2710
76. For a discussion of ipso and ω addition to multihapto π complexes, see Ref. 18. For the ω directing nature of aryl substituents on cyclohexadienyliron complexes, see Ref. 3. In this case, the presence of the 4-OMe group helps overcome the natural ω selectivity and promote the ipso pathway (ipso relative to the position of the arene). This is because the C(4) OMe is also ω directing (see Ref. 31), and the two control effects are opposed (for definitions of the terms 'mutually reinforcing' and 'opposed' in the context of nucleophile addition to multiply substituted ligands, see Ref. 18).
77. For examples with opposed Me and OMe groups:. Pearson A.J., and Perrior T.R. J. Organomet. Chem. 285 (1985) 253-265
78. Pearson A.J., and Ham P. J. Chem. Soc., Perkin Trans. 1 (1983) 1421-1425
79. Pearson A.J., Ham P., and Rees D.C. J. Chem. Soc., Perkin Trans. 1 (1982) 489-497
80. Tao C., and Donaldson W.A. J. Org. Chem. 58 (1993) 2134-2143
81. We used a similar approach towards the terpene tridachione:. Stephenson G.R. J. Chem. Soc., Perkin Trans. 1 (1982) 2449-2456
82. Alexander R.P., James T.D., and Stephenson G.R. J. Chem. Soc., Dalton Trans. (1987) 2013-2016
83. Roe, C.; Stephenson, G. R. Org. Lett., submitted for publication.